Identifying Efficacious Thresholds for Bleeding Risk Reduction in Relation to Factor IX (FIX) Levels in Hemophilia B Patients Receiving IDELVION

被引：0
|
作者：
Fosser, C. [1 ]
Roberts, J. [2 ]
Tortorici, M. [2 ]
Jacobs, I. [2 ]
Sidhu, J. [2 ]
机构：
[1] Cytel, Cambridge, MA USA
[2] CSL Behring, King Of Prussia, PA USA
来源：
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS | 2017年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
M-010
引用
收藏
页码：S15 / S15
页数：1
相关论文
共 50 条
  • [1] Bleeding Risk Reduction in Relation to Predicted Factor IX Levels in Hemophilia B Patients Receiving Idelvion (rIX-FP)
    Roberts, John
    Fosser, Cecilia
    Tortorici, Michael
    Veldman, Alex
    Jacobs, Iris C.
    Sidhu, Jagdev
    BLOOD, 2016, 128 (22)
  • [2] HEMOPHILIA-B WITH PROLONGED BLEEDING-TIME, ABNORMAL FACTOR-IX (FIX SAUDA) AND HYPERACTIVE FACTOR-IX ALLELE
    STORMORKEN, H
    LEFKOWITZ, J
    MONROE, DM
    HIGH, KA
    ROBERTS, H
    THROMBOSIS AND HAEMOSTASIS, 1991, 65 (06) : 966 - 966
  • [3] Monitoring IgE and IgG subclasses in hemophilia B patients with factor IX (FIX) inhibitors.
    Leitermann, K
    Berntorp, E
    Ewenstein, BM
    Sommer, S
    Thompson, AR
    Rup, BJ
    BLOOD, 1997, 90 (10) : 145 - 145
  • [4] Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A
    Collins, P. W.
    Blanchette, V. S.
    Fischer, K.
    Bjorkman, S.
    Oh, M.
    Fritsch, S.
    Schroth, P.
    Spotts, G.
    Astermark, J.
    Ewenstein, B.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 (03) : 413 - 420
  • [5] Identification of effective factor VIII thresholds for bleeding risk reduction in patients with haemophilia A receiving rVIII-SingleChain
    McKeand, W.
    Fosser, C.
    Roberts, J.
    Goldstein, B.
    Li, Y.
    Tortorici, M.
    HAEMOPHILIA, 2019, 25 : 58 - 58
  • [6] Identifying hemophilia B carriers: Utility of aPTT, factor IX levels and ratios of factor IX to other Vitamin K dependent factors
    Shu, Michael
    Malcolmson, Caroline
    Bosch, Alessandra
    Markovic, Teodora
    Wakefield, Cindy
    Bouskill, Vanessa
    Carcao, Manuel
    HAEMOPHILIA, 2024, 30 (04) : 1003 - 1009
  • [7] Bleeding events and factor IX levels in female carriers from a large kindred of hemophilia B.
    Salter, John T.
    Hardesty, Brandon
    Heiman, Meadow
    Sulkin, Matthew
    Shapiro, Amy D.
    Greist, Anne
    BLOOD, 2007, 110 (11) : 349A - 349A
  • [8] THE USE OF A HIGHLY PURIFIED FACTOR-IX (FIX) CONCENTRATE IN PATIENTS WITH HEMOPHILIA-B UNDERGOING SURGERY
    HO, PJ
    RICKARD, KA
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1995, 25 (01): : 43 - 45
  • [9] Bleeding Data across Baseline FIX Expression Levels in People with Hemophilia B: An Analysis Using the 'Factor Expression Study'
    Burke, Tom
    Shaikh, Anum
    Ali, Talaha
    Li, Nanxin
    Konkle, Barbara A.
    Noone, Declan
    O'Mahony, Brian
    Pipe, Steven W.
    O'Hara, Jamie
    BLOOD, 2021, 138
  • [10] Subcutaneous recombinant factor IX (beneFIX(TM)) administration produces therapeutic levels of FIX activity in hemophilia B dogs.
    Brinkhous, KM
    Sigman, JL
    Read, MS
    Stewart, PF
    Bush, L
    Bartlett, E
    Rup, B
    Keith, JC
    Garzone, P
    McCarthy, K
    Schaub, RG
    BLOOD, 1996, 88 (10) : 1757 - 1757
12345